Extended Continuous Oral Temozolomide in Patients with Progressive Metastatic Renal Cell Carcinoma Not Responding to Interferon Alpha 2b

References

• Flanigan RC, Yonover PM. The role of radical nephrec-tomy in metastatic renal cell carcinoma. Semin Oncol 2001; 19 (2): 98–102.
   Google Scholar
• Bleumer I, Oosterwijk E, De Mulder PH, Mulders PFA. Immunotherapy for renal cell carcinoma. Eur Urol 2003; 44: 65–75.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bacik J, Mazumdar M. Prognostic factors for survival of patients with stage IV renal cell carcinoma: Memorial Sloan-Kettering Cancer Center experience. Clin Cancer Res 2004; 10 ((Suppl.)): 6302s-6303s.
   Google Scholar
• Brada M, Viviers L, Abson C, Hines F, Britton J, Ashley S et al. Phase II study of primary temozolomide chemothera-py in patients with WHO grade II gliomas. Ann Oncol 2003; 14 (12): 1715–1721.
   Google Scholar
• Dhodapkar M, Rubin J, Reid JM, Burch PA, Pitot HC, Buckner JC et al. Phase I trial of temozolomide (NSC 362856) in patients with advanced cancers. Clin Cancer Res 1997; 3 (7): 1093–1100.
   PubMed Web of Science ®Google Scholar
• Newlands ES, Blackledge GR, Slack JA, Rustin CJ, Smith DB, Stuart NS et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 1992; 65 (2): 287–291.
   PubMed Web of Science ®Google Scholar
• Adonizio CS, Babb JS, Maiale C, Huang C, Donahue J, Millenson MM et al. Temozolomide in non-small-cell lung can-cer: preliminary results of a phase II trial in previously treated patients. Clin Lung Cancer 2002; 3 (4): 254–258.
   PubMedGoogle Scholar
• Raymond E, Izbicka E, Soda H, Gerson SL, Dugan M, von Hoff DD. Activity of temozolomide against human tumor colony-forming units. Clin Cancer Res 1997; 3:1769.
   PubMed Web of Science ®Google Scholar
• Bafaloukos D, Tsoutsos D, Fountzilas G, Linardou H, Christodoulou C, Kalofonos HP et al. The effect of temozolo-mide-based chemotherapy in patients with cerebral metastases from melanoma. Melanoma Res 2004; 14 (4): 289–294.
   PubMed Web of Science ®Google Scholar
• Ebert BL, Niemierko E, Shaffer K, Salgia R. Use of temozolomide with other cytotoxic chemotherapy in the treat-ment of patients with recurrent brain metastases from lung cancer. Oncologist 2003; 8 (1): 69–75.
   PubMed Web of Science ®Google Scholar
• Reni M, Mason W, Zaja F, Perry J, Franceschi E, Bernardi D et al. Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. Eur J Cancer 2004; 40 (11): 1682–1688.
   Google Scholar
• Park DK, Ryan CW, Dolan ME, Vogelzang NJ, Stadler WM. A phase II trial of oral temozolomide in patients with metastatic renal cell cancer. Cancer Chemother Pharmacol 2002; 50: 160–162.
   PubMed Web of Science ®Google Scholar
• Sunkara U, Walczak JR, Summerson L, Rogers T, Eisenberger M, Denmeade S et al. A phase II trial of temo-zolomide and IFN-alpha in patients with advanced renal cell carcinoma. J Interferon Cytokine Res 2004; 24 (1): 37–41.
   Google Scholar
• Tolcher AW, Gerson SL, Denis L, Geyer C, Hammond LA, Patnaik A et al. Marked inactivation of 06-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 2003; 88: 1044–1011.
   Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92 (3): 205–216.
   PubMed Web of Science ®Google Scholar
• Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10 (1): 1–10.
   PubMedGoogle Scholar
• Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20 (1): 289–296.
   PubMed Web of Science ®Google Scholar
• Tano K, Shiota S, Collier J, Foote RS, Mitra S. Isolation and structural characterization of a cDNA clone encoding the human DNA repair protein for 06-alkylguanine. Proc Nat Acad Sci USA 1990; 87: 686–690.
   PubMed Web of Science ®Google Scholar
• Jaeckle KA, Eyre HJ, Townsend JJ, Schulman S, Knudson HM, Belanich M et al. Correlation of tumor 06 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylni-trosurea: a Southwest Oncology Group Study. J Clin Oncol 1998; 16: 3310–3315.
   Google Scholar
• Dumenco LL, Warman B, Hatzoglou M, Lim IK, Abboud SL, Gerson SL. Increase in nitrosurea resistance in mammalian cells by retrovirally mediated gene transfer of bac-terial 06-alkylguanine-DNA alkyltransf erase. Cancer Res 1989; 49: 6044-6051.
   Google Scholar
• Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000; 343: 1350–1354.
   Google Scholar
• Paz MF, Yaya-Tur R, Rojas-Marcos I, Reynes G, Pollan M, Aguirre-Cruz L et al. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 2004; 10 (15): 4933–4938.
   Google Scholar
• Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S et al. clinical trial substantiates the predictive value of 0-6-methylguanine-DNA-methyltransferase promoter methylation in glioblastoma patients treated with temozolo-mide. Clin Cancer Res 2004; 10 (6): 1871-1874.
   Google Scholar
• Brock CS, Newlands ES, Wedge SR, Bower M, Evans H, Colquhoun I et al. Phase I trial of temozolomide using an extended continous oral schedule. Cancer Res 1998; 58 (19): 4363–4367.
   Google Scholar
• Willson JK, Haaga JR, Trey JE, Stellato TA, Gordon NH, Gerson SL. Modulation of 06-alkylguanine alkyltrans-ferase-directed DNA repair in metastatic colon cancers. J Clin Oncol 1995; 13: 2301-2308.
   Google Scholar
• Spiro TP, Gerson SL, Liu L, Majka S, Haaga J, Hoppel CL et al. 06-benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltrans-f erase-directed DNA repair. Cancer Res 1999; 59: 2402-2410.
   Google Scholar
• Spiro TP, Liu L, Majka S, Haaga J, Willson JK, Gerson SL. Temozolomide: the effect of once- and twice-a-day dosing on tumor tissue levels of the DNA repair protein 0 (6) -alkylguanine-DNA-alkyltransferase. Clin Cancer Res 2001; 7 (8): 2309–2317.
   PubMed Web of Science ®Google Scholar
• Wedge SR, Porteous JK, Newlands ES. Effect of single and multiple administration of an 06-benzylguanine/temozolo-mide combination: an evaluation in a human melanoma xenograft model. Cancer Chemother Pharmacol 1997; 40: 266–272.
   PubMed Web of Science ®Google Scholar
• Khan RB, Raizer JJ, Malkin MG, Bazylewicz KA, Abrey LE. A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neuro-Oncol 2002; 4 (1): 39–43.
   PubMed Web of Science ®Google Scholar
• Trent JC, Beach J, Burgess MA, Papadopoulos N, Chen LL, Benjamin RS et al. A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stro-mal tumors and other soft tissue sarcomas. Cancer 2003; 98 (12): 2693–2699.
   PubMed Web of Science ®Google Scholar
• Barvaux VA, Ranson M, Brown R, McElhinney RS, McMurry TB, Margison GP. Dual repair modulation reverses temozolomide resistance in vitro. Mol Cancer Ther 2004; 3 (2): 123–127.
   PubMed Web of Science ®Google Scholar
• Deguchi M, Shiina H, Igawa M, Kaneuchi M, Nakajima K, Dahiya R. DNA mismatch repair genes in renal cell carci-noma. J Urol 2003; 169 (6): 2365–2371.
   PubMed Web of Science ®Google Scholar